← Leaderboards
Cynthia Arbeeny
Mitotherapeutix, Llc
$1,061,146
Attributed
$2,122,291
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2021–23$2M$1.5M$1M$500K$0
'21
'22
'23
Funding mix
By agency
NIH$2,122,291 · 1
By mechanism
R44$2,122,291 · 1
Top collaborators
- Mercedes R. Rincon3 shared
Others in their field
Other Emerging Leaders on “Acetylgalactosamine”
- Guizhi Zhu · Virginia Commonwealth University$1,647,829
- Jacob Litke · Weill Medical Coll Of Cornell Univ$1,498,076
- Juan Pablo Idrovo · University Of Colorado Denver$670,804
- Justyn Jaworski · University Of Texas Arlington$373,209
- Jace W Jones · University Of Maryland Baltimore$266,621
- Steven Fletcher · University Of Maryland Baltimore$266,621
Research focus
AcetylgalactosamineFatty Acid TransportBioinformaticsCirrhosisClinical ResearchCommercializationCostCountryCoupledCross ReactivityDesignDiabetes MellitusDiagnosisDisease ModelDoseDrug CandidateDrug DevelopmentDrug DiscoveryElectronsElectron TransportExcisionFatty Acid Glycerol EstersFatty AcidsFda Approved
Grant awards (3)
A novel approach to treat non-alcoholic steatohepatitis (NASH)$1,008,980
R44 · FY2023 · DK · contact PI
A novel approach to treat non-alcoholic steatohepatitis (NASH)$860,261
R44 · FY2022 · DK · contact PI
A novel approach to treat non-alcoholic steatohepatitis (NASH)$253,050
R44 · FY2021 · DK · contact PI